ctDNA offers a non-invasive way to track Multiple Myeloma, reducing the need for painful bone marrow biopsies Detects genetic mutations, treatment resistance, and disease progression before ...

Alexander Spira, MD, PhD, FACP, discusses the PAPILLON trial, including its methods, design, and rationale as well as new data from the study. Alexander Spira, MD, PhD, FACP, director of the Virginia ...

I know a lot of you see a lot of patients with lung cancer, so in a scenario like this, would you consider doing any sort of circulating tumor DNA [ctDNA] assay or any other element that would help ...

In conclusion, ctDNA methylation in both tissue and plasma can effectively differentiate malignancy from benign disease and holds great potential as a biomarker for early lung cancer diagnosis.

A NEW STUDY has demonstrated the clinical utility of circulating tumour DNA (ctDNA) analysis as an alternative to tissue biopsy for genotyping in advanced urothelial cancer (UC). Researchers aimed to ...

circulating tumor DNA (ctDNA), which is released into the bloodstream by tumor cells, offers a promising non-invasive alternative. It allows for real-time monitoring and comprehensive genetic ...

New findings of the Stratified Medicine Paediatrics (SMPaeds1) programme, published in the journal Cancer Discovery, have successfully demonstrated that circulating tumour DNA (ctDNA) testing can be ...

For MIBC, innovative approaches like TAR-200 plus cetrelimab and ctDNA-guided post-cystectomy immunotherapy demonstrated promising outcomes, while durvalumab with chemotherapy in the NIAGARA trial ...

National Comprehensive Cancer Network® (NCCN®) Guidelines for colon and rectal cancer were updated to include ctDNA as a prognostic marker and high risk factor for recurrence NCCN guideline for ...

Additionally, we will briefly touch on different types of tests such as ctDNA and MRD to provide a sense of the testing landscape. Webinar 2 will focus on specimen types, specimen management, ...